BACKGROUND: Recent clinical observations suggested that COVID-19 mRNA vaccines prime innate and adaptive immunity and enhance anti-tumor immune responses, leading to improved survival of patients with cancers.
METHODS: We analyzed the cohort of patients with advanced cancers receiving COVID-19mRNA vaccine and treated in a Comprehensive Cancer Centre in 2021. Among these, 281 patients received ICI. The overall survival (OS) of patients receiving at least one mRNA SARS-CoV-2 dose within 100 days before ICI initiation were compared with all other patients. OS was measured from the first date of ICI administration. Cox proportional hazards models with backward selection was used to identify variables significant in univariable analyses. The study was approved with the MR004 methodology on Oct 31st 2025.
RESULTS: Among 281 patients, 47 (16.7%) received an mRNA vaccine within 100 days before starting ICI. Baseline characteristics, tumor types and ICI agents were balanced across groups. After a median follow-up of 51 months, OS was significantly improved in patients vaccinated within 100 days prior to ICI (median 51.0 months, 95%CI 33.9-70.0) compared with others (21.0 months, 95%CI 17.7-24.3; p = 0.012). In multivariate analysis, younger age (p = 0.002), female sex (p = 0.003), non-head and neck tumors (p = 0.041), and COVID-19 mRNA vaccination within 100 days before ICI (HR 0.615; 95%CI 0.407-0.928; p = 0.021) remained independently associated with improved OS.
CONCLUSIONS: In this cohort including multiple cancer types, administration of COVID-19 mRNA vaccine within 100 days before ICI initiation was independently associated with superior long-term overall survival. These data warrant prospective confirmation.